» Articles » PMID: 16610025

Gastrointestinal Stromal Tumors in a Cohort of Chinese Patients in Hong Kong

Overview
Specialty Gastroenterology
Date 2006 Apr 13
PMID 16610025
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: To investigate the prevalence and clinical pattern of gastrointestinal stromal tumors (GISTs) in Hong Kong Chinese, and to assess the impact of introduction of CD117 on the disease incidence.

Methods: From the database of the Department of Pathology of Yan Chai Hospital, 47 patients, with GISTs from September 1995 to December 2003 were included in this study. Ten GISTs were diagnosed before the introduction of CD117. The clinical features, tumor characteristics, and treatment were analyzed. Factors predicting tumor related death or recurrence were studied with Cox proportional hazard model.

Results: The patients included 26 males and 21 females, with a mean age of 66.6 years (SD 13.1, range 29-87 years). The estimated prevalence of GISTs was 13.4-15.6 per 100,000 people, with an annual incidence of 1.68-1.96 per 100,000 people. The annual incidence of GISTs before and after the introduction of CD117 was 1.1 per 100,000 people and 2.1 per 100,000 people respectively. Stomach (34 patients, 72.3%) was the most common location for the tumor, followed by the small intestine (8 patients, 17.0%), esophagus (2 patients, 4.3%), omentum (2 patients, 4.3%) and colon (1 patient, 2.1%). Thirty-one patients (66%) had complete tumor resection. Eleven out of 16 deaths (23%) were tumor-related. The median survival time was 26 mo. Five-year survival rate was 61.3%. The significant factors associated with tumor-related death or recurrence were incomplete resection, tumor size 5 cm or above, invasion to the adjacent organ or presence of metastasis.

Conclusion: The incidence of GIST in Hong Kong is comparable to that in the United States but lower than that in Finland. The true incidence of GISTs could be underestimated before the introduction of CD117. Incomplete resection, tumor size 5 cm or above, invasion to the adjacent organ or presence of metastasis are factors predicting tumor-related death or recurrence.

Citing Articles

KIT ATP-Binding Pocket/Activation Loop Mutations in GI Stromal Tumor: Emerging Mechanisms of Kinase Inhibitor Escape.

Muhlenberg T, Falkenhorst J, Schulz T, Fletcher B, Teuber A, Krzeciesa D J Clin Oncol. 2024; 42(12):1439-1449.

PMID: 38408285 PMC: 11095889. DOI: 10.1200/JCO.23.01197.


[Gastrointestinal stromal tumors: a retrospective study].

Zidane H, Kebbati Z, Khettab M Pan Afr Med J. 2023; 45:97.

PMID: 37692978 PMC: 10491712. DOI: 10.11604/pamj.2023.45.97.36563.


Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision.

Unk M, Novakovic B, Novakovic S Cancers (Basel). 2023; 15(5).

PMID: 36900287 PMC: 10001062. DOI: 10.3390/cancers15051498.


Role of Surgery in the Management of Liver Metastases From Gastrointestinal Stromal Tumors.

Xue A, Gao X, He Y, Shu P, Huang X, Sun J Front Oncol. 2022; 12:903487.

PMID: 35847933 PMC: 9283564. DOI: 10.3389/fonc.2022.903487.


Preventive Effect of Intensive Nursing Intervention of Deep Vein Thrombosis of Lower Extremities in Elderly Patients with Gastrointestinal Tumors after Surgery.

Li Y, Xiao F J Oncol. 2022; 2022:2967981.

PMID: 35518786 PMC: 9064512. DOI: 10.1155/2022/2967981.


References
1.
Evans H . Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer. 1985; 56(9):2242-50. DOI: 10.1002/1097-0142(19851101)56:9<2242::aid-cncr2820560918>3.0.co;2-5. View

2.
Yu C, Fletcher C, Newman P, Goodlad J, Burton J, Levison D . A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours. J Pathol. 1992; 166(2):147-52. DOI: 10.1002/path.1711660210. View

3.
Franquemont D . Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995; 103(1):41-7. DOI: 10.1093/ajcp/103.1.41. View

4.
Bucher P, Villiger P, Egger J, Buhler L, Morel P . Management of gastrointestinal stromal tumors: from diagnosis to treatment. Swiss Med Wkly. 2004; 134(11-12):145-53. DOI: 10.4414/smw.2004.10530. View

5.
Ballarini C, Intra M, Ceretti A, PRESTIPINO F, Bianchi F, Sparacio F . Gastrointestinal stromal tumors: a "benign" tumor with hepatic metastasis after 11 years. Tumori. 1998; 84(1):78-81. DOI: 10.1177/030089169808400117. View